依折麦布联合阿托伐他汀改善PCI后患者血脂代谢的临床研究

Clinical research of ezetimibe combined with atorvastatinon improving lipid metabolism in patients after percutaneous coronary intervention surgery

目的观察依折麦布联合阿托伐他汀对经皮冠状动脉介入治疗(PCI)后患者血脂代谢的影响。方法根据患者降脂治疗方案不同随机分为依折麦布联合阿托伐他汀组(依折麦布组)和单用阿托伐他汀组(阿托伐他汀组),治疗6个月后复查血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和血清高敏C反应蛋白(hs-CRP),比较两组主要不良心脑血管事件(MACCE)发生情况。结果治疗后依折麦布组血清TC[(3.05±0.78)vs.(4.23±0.91),P=0.041]、LDL-C[(1.96±0.80)vs.(2.43±0.97),P=0.037]和hs-CRP[(2.60±4.96)vs.(3.74±4.48),P=0.044]较阿托伐他汀组显著降低(P<0.05);依折麦布组患者MACCE发生率低于阿托伐他汀组[6(6.83%)vs.15(17.65%),P=0.029]。结论依折麦布联合阿托伐他汀可更好改善PCI后患者血清TC、LDL-C和hs-CRP,减少发生MACCE的风险,可能成为PCI后患者优化降脂治疗的新选择。

Objective To observe the effect of ezetimibe combined with atorvastatin on the blood lipid metabolism in patients after percutaneous coronary intervention(PCI).Methods According to different lipidlowering treatments,patients were randomly divided into ezetimibe combined with atorvastatin group(ezetimibe group)and atorvastatin alone group(atorvastatin group).Six months after treatment,serum total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C)and serum high-sensitivity C-reactive protein(hs-CRP)were reviewed,and the occurrence of major adverse cardio-cerebrovascular events(MACCE)was compared between the two groups.Results Compared with the atorvastatin group,the serum levels of TC[(3.05±0.78)vs.(4.23±0.91),P=0.041)],LDL-C[(1.96±0.80)vs.(2.43±0.97),P=0.037)],and hs-CRP[(2.60±4.96)vs.(3.74±4.48),P=0.044)]were significantly lower in ezetimibe group,and the incidence of MACCE[6(6.83%)vs.15(17.65%),P=0.029]was significantly lower in ezetimibe group.Conclusion Ezetimibe combined with atorvastatin can effectively improve serum TC,LDL-C and hs-CRP levels in patients after PCI surgery,and also reduce the incidence of MACCE.